The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis.

Autor: Lupas D; Schulich School of Medicine, Western University, London, Ontario, Canada., Chou FY; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada., Hakani MAA; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Kuthiala I; Schulich School of Medicine, Western University, London, Ontario, Canada., Srikrishnaraj A; Schulich School of Medicine, Western University, London, Ontario, Canada., Li X; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada., Potter N; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada., Quon BS; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: bradley.quon@hli.ubc.ca.

Publikováno v: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2024 Sep; Vol. 23 (5), pp. 950-958. Date of Electronic Publication: 2024 Jul 23.